Delayed-release capsule pairs Bifidobacterium lactis, longum and breve at 9 billion CFUs with xylooligosaccharides and tributyrin; company details capsule technology designed to survive stomach acid and cites general strain research alongside its own label
SAN FRANCISCO, Calif. — September 30, 2026 — Bioma.health has released a research summary examining the published science behind the supporting ingredients and delivery format of Bioma Probiotics, placing the amounts on its label alongside the doses and test conditions used in peer-reviewed and laboratory studies. The document is a companion to the company’s earlier strain-level disclosure.
The release arrives as terms such as “synbiotic” and “postbiotic” appear more frequently on supplement packaging, sometimes without an explanation of what separates one from the other or whether the amounts on a label resemble the amounts used in research. The company says its summary is intended to help readers judge that gap for themselves rather than to make a claim about what the product does.
“A label can name a well-studied ingredient and still differ a great deal from the study that made it well known,” said Dr. Kevin Moore, Product Head at Bioma. “We compared our stated amounts with published trial doses so that readers can see where the research is a close match, where it is not, and where no study exists.”
Three Terms, Three Different Jobs
The summary begins by separating three concepts that are often blurred together. A probiotic is a live microorganism. A prebiotic is a substrate, usually a non-digestible fiber, that resident gut bacteria can ferment. A butyrate source, such as tributyrin, supplies a short-chain fatty acid that gut bacteria normally produce themselves when they ferment fiber. Bioma Probiotics contains an ingredient from each of these groups, which the company describes as a synbiotic-style design. The summary notes that this description refers to the composition of the label. It is not a statement that the combination has been tested as a unit.
What Published Trials Say About Xylooligosaccharides
Xylooligosaccharides (XOS) are chains of xylose sugar units that human digestive enzymes do not break down. A 2014 study in Food & Function enrolled 32 healthy adults in a double-blind, randomized, placebo-controlled design lasting eight weeks, with participants receiving 1.4 grams of XOS, 2.8 grams of XOS or placebo daily. The investigators reported that XOS increased bifidobacteria but not lactobacilli in the gut microbiota, and that the effect was seen at a dose as low as 1.4 grams per day.[1]
A separate 2014 trial in the British Journal of Nutrition used a higher dose. Healthy adults aged 25 to 65 received 8 grams of XOS per day, one billion CFUs per day of the Bifidobacterium animalis subsp. lactis strain Bi-07, or both, for 21 days in a double-blind, placebo-controlled, cross-over design. XOS supplementation increased the average number of daily bowel movements and raised participant-reported vitality and happiness scores, without increasing reported bloating, abdominal pain or flatulence compared with the maltodextrin comparator.[2] A smaller 2016 study of 20 healthy adults over six weeks examined XOS delivered in rice porridge and reported effects on the balance of gut bacteria.[3]
Bioma’s label lists 100 milligrams of XOS per serving. That is roughly one-fourteenth of the lowest daily amount used in the 2014 Food & Function study and about one-eightieth of the amount used in the British Journal of Nutrition trial. The summary states that the trials cited here therefore cannot be read as evidence of the same effects at Bioma’s labeled amount. The studies also enrolled healthy volunteers and did not evaluate Bioma’s formula.
The company adds that the Bi-07 strain used in the second trial is a strain of Bifidobacterium lactis, the same species named on Bioma’s label. Because Bioma does not identify a sub-strain, the comparison illustrates how a synbiotic is studied, not what Bioma’s specific combination does.
Tributyrin: Strong Mechanism, Limited Human Data
Butyrate is a short-chain fatty acid that serves as a primary fuel for the cells lining the colon. Taken by mouth in its simple form, most butyrate is absorbed in the small intestine, and relatively little reaches the colon. Tributyrin is a compound in which three butyrate units are bound to a glycerol backbone. It must be broken down by digestive enzymes before butyrate is released, which is the basis for interest in it as a way of moving butyrate further along the digestive tract.
A 2025 laboratory study published in Frontiers in Nutrition tested a branded tributyrin product in a simulated upper digestive tract. In that model, about 41 percent of the dose in a capsule format and about 49 percent in a softgel format was converted to butyrate in the small intestine, and the remainder stayed intact and was available to reach the colon. In a separate gut-simulator model run for three weeks, daily tributyrin increased butyrate levels and the abundance of several bacterial groups, including Bifidobacterium species.[4] The authors worked with a specific branded ingredient, in vitro, using simulated conditions rather than human participants.
Human data are thinner. A pilot study registered as NCT05601635 and published in Nutrition and Healthy Aging in 2024 randomized 29 healthy adults to one of two doses of a proprietary tributyrin complex for 28 days, with tolerability, gut microbiome composition, gut permeability and inflammation markers as areas of assessment.[5] The design was single-blinded, small and short, and it used a different tributyrin product than the one listed on Bioma’s label. The summary does not extrapolate from it.
Bioma lists 90 milligrams of tributyrin per serving. The company states that it is not aware of a published human trial that used this amount in combination with the other ingredients in its formula. Findings for one tributyrin preparation should not be assumed to apply to another.
Find more details about ingredients of Bioma Probiotics on their official website.
How Capsule Survival Is Actually Tested
The third section addresses the delayed-release capsule. Delivery claims are engineering claims, and the research literature on them is largely laboratory-based. A 2013 study compared commercial probiotic products by exposing them to simulated gastric fluid for 120 minutes and then simulated intestinal fluid for 180 minutes, using United States Pharmacopeia preparation protocols, and counting bacteria before and after. Four capsules with an enteric coating showed better survival than uncoated products. Eight encapsulated products without an enteric coating showed limited resistance, and five products showed no survival through the simulated transit. The authors concluded that gastrointestinal survival varies from one product to another.[6]
A 2024 paper in Heliyon examined a freeze-dried Lactobacillus acidophilus strain in capsules coated with a pH-sensitive polymer. Those capsules did not disintegrate in simulated gastric fluid and did disintegrate in simulated intestinal fluid, and the coating process left about 95 percent of viable cells intact.[7] The work involved a different organism and a laboratory model.
The company’s summary draws two conclusions from this literature. First, capsule design can matter, and products differ. Second, a manufacturer’s description of a delayed-release capsule is not a substitute for survival data on the finished product. The summary notes that Bioma’s public materials do not cite independent third-party testing of its capsule, and that readers seeking that kind of evidence should ask for it directly from any supplement maker, not only Bioma.
Reading a Supplement Label Against the Research
The summary closes with a short set of questions the company suggests readers can apply to any probiotic, prebiotic or butyrate product:
Does the label name the strain, not only the species? Is the amount of each active ingredient stated, and how does it compare with the amount used in the study being cited? Was the study conducted in people, in animals or in a laboratory model? Did it test the finished product, or an ingredient on its own? Who funded it, and was there a placebo group? Does the manufacturer provide testing on how the capsule or tablet performs?
The company notes that some of the studies referenced in its summary tested branded or proprietary ingredients, and that no study cited here evaluated the complete Bioma formula. It recommends reading study methods and not only conclusions.
Purchase and Refund Terms
Bioma Probiotics is sold in 1-, 3,- and 6-month package configurations with bundle discounts. Consumers should confirm current pricing and refund terms directly on the official checkout page before purchase, since bundle structures and promotional pricing in this category are commonly time-limited.
Manufacturing and Usage Notes
Bioma states that the product is manufactured in an FDA-registered, GMP-certified facility in the United States. GMP practices address consistency and quality control in production and do not amount to FDA evaluation of a supplement’s effectiveness. The labeled serving is two capsules daily. People who are pregnant, nursing, taking prescription medication, or managing a gastrointestinal or immune-related condition are advised by the company to consult a healthcare professional before use. Readers should follow the current physical label for serving directions and warnings.
Frequently Asked Questions
Do the XOS studies apply to the amount in Bioma?
Not directly. The trials cited used daily amounts from 1.4 grams to 8 grams, while Bioma’s label lists 100 milligrams per serving.
Has tributyrin been tested in people?
Some small human studies exist, including a 29-person pilot, but they used other tributyrin products and doses. Much of the mechanistic data comes from laboratory and animal models.
Does a delayed-release capsule guarantee bacterial survival?
No. Laboratory studies show survival differs between products, and Bioma’s Probiotics public materials do not include independent testing of its capsule.
Is this summary a clinical evaluation of Bioma? No. It is a review of published research on individual components and delivery formats, prepared to help readers read labels more critically.
About Bioma Health
Bioma Health is the parent company of Bioma Probiotics, with operations in San Francisco, California, and Mamavys, Lithuania. The company manufactures Bioma at a facility it identifies as FDA-registered and GMP-certified in the United States.
References
[1] Finegold SM, Li Z, Summanen PH, et al. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food & Function. 2014;5:436-445. doi:10.1039/c3fo60348b
[2] Childs CE, Röytiö H, Alhoniemi E, et al. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. British Journal of Nutrition. 2014;111(11):1945-1956. doi:10.1017/S0007114513004261
[3] Lin SH, Chou LM, Chien YW, Chang JS, Lin CI. Prebiotic Effects of Xylooligosaccharides on the Improvement of Microbiota Balance in Human Subjects. Gastroenterology Research and Practice. 2016;2016:5789232. doi:10.1155/2016/5789232
[4] Tributyrin (CoreBiome) enhances butyrate levels and modulates the gut microbiota, barrier function, and immune response in vitro. Frontiers in Nutrition. 2025. doi:10.3389/fnut.2025.1712993
[5] Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study. Nutrition and Healthy Aging. 2024. doi:10.3233/NHA-240005. ClinicalTrials.gov, NCT05601635.
[6] Simulated gastrointestinal transit study of commercial probiotic capsules, fermented milk and powder products. 2013. New Century Health Publishers.
[7] Fredua-Agyeman M. Surviving process and transit: Controlled freeze drying, storage and enteric coated capsules for targeted delivery of probiotic Lactobacillus acidophilus. Heliyon. 2024;10(7):e28407. doi:10.1016/j.heliyon.2024.e28407
Media Contact
Kevin Moore, Product Head,
Bioma health 315 Montgomery Street,
San Francisco, CA 94104
Email: hello@bioma.health
Help Center: help.bioma.health
Disclaimer: Bioma Probiotics is a dietary supplement. These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Research referenced in this release concerns individual ingredients, products and delivery formats studied independently and does not constitute clinical evaluation of the complete Bioma formula. Individual responses to probiotic supplementation may vary. Consult a qualified healthcare professional before use, particularly if pregnant, nursing, managing an existing medical condition, or taking prescription medication.
